Evidence map›Paper›PMID 28223256›Full record

ReviewAnaerobe2017

Role of the leukocyte response in normal and immunocompromised host after Clostridium difficile infection.

Edwin Vargas, Senu Apewokin, Rajat Madan

Abstract readReview
In one paragraph

Review in Anaerobe, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 23 citations in OpenAlex.

  1. Epidemiology ofAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Management ofEClinicalMedicine · 2025
    Review
  4. Derivation and internal validation of the multivariate toxigenicAntimicrobial stewardship & healthcare epidemiology : ASHE · 2024
    Article
  5. Performance of Clostridioides difficile infection severity scores and risk factors related to 30-day all-cause mortality in patients with cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023
    Observational
  6. Cytotoxic synergism ofWorld journal of gastroenterology · 2023
    Review
  7. Article
  8. Article
  9. Invisible steps for a global endemy: molecular strategies adopted byTherapeutic advances in gastroenterology · 2021
    Review
  10. Article
  11. Article
  12. TargetingFrontiers in microbiology · 2018
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Edwin VargasDivision of Infectious Diseases, Department of Internal Medicine, University of Cincinnati, 231 Albert Sabin Way, MSB 6109, ML 0560, Cincinnati, OH 45267, USA. Electronic address: vargasen@ucmail.uc.edu.
Senu ApewokinDivision of Infectious Diseases, Department of Internal Medicine, University of Cincinnati, 231 Albert Sabin Way, MSB 6109, ML 0560, Cincinnati, OH 45267, USA.
Rajat MadanDivision of Infectious Diseases, Department of Internal Medicine, University of Cincinnati, 231 Albert Sabin Way, MSB 6109, ML 0560, Cincinnati, OH 45267, USA.
Sabin Vaccine Institute · USUniversity of Cincinnati · US

Funding

Role of leptin in mucosal protection during Clostridium difficile infectionK08AI108801 · NIAID · UNIVERSITY OF VIRGINIA · PI MADAN, RAJAT · 2014 to 2018
$880k
NIAID NIH HHS K08 AI108801
6 · The paper itself

Abstract

Clostridium difficile is the leading cause of healthcare-associated infections in the United States. Clinically, C. difficile-associated disease can present as asymptomatic colonization, self-limited diarrheal illness or severe colitis (that may result in death). This variability in disease course and outcomes suggests that host factors play an important role as key determinants of disease severity. Currently, there are several scoring indices to estimate severity of C. difficile-associated disease. Leukocytosis and renal failure are considered to be the most important predictors of C. difficile disease severity in hosts with a normal immune system. The degree of leukocytosis which is considered significant for severe disease and how it is scored vary amongst scoring indices. None of the scores have been prospectively validated, and while total WBC count is useful to estimate the magnitude of the host response in most patient populations, in immune-compromised patients like those receiving chemotherapy, solid organ transplant patients or hematopoietic stem cell transplants the WBC response can be variable or even absent making this marker of severity difficult to interpret. Other cellular subsets like neutrophils, eosinophils and lymphocytes provide important information about the host immune status and play an important role in the immune response against C. difficile infection. However, under the current scoring systems the role of these cellular subsets have been underestimated and only total white blood cell counts are taken into account. In this review we highlight the role of host leukocyte response to C. difficile challenge in the normal and immunocompromised host, and propose possible ways that would allow for a better representation of the different immune cell subsets (neutrophils, lymphocytes and eosinophils) in the current scoring indices.

Indexed as

Immunocompromised HostClostridium InfectionsHumansLeukocytesLeukocytosisProspective StudiesClostridium difficileDisease severityLeukocytosis

Identifiers

PMID28223256
PMCPMC5531608
OpenAlexW2591445778

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.